AUS
NZ
UK
CA
USA
IND
Highlights
- 4DMedical partners with global firms on advanced lung disease therapies.
- Software to support clinical trials for COPD and implantable lung device.
- U.S. veterans’ healthcare initiative integrates 4DMedical’s diagnostic tech.
4DMedical’s (ASX:4DX) cutting-edge lung imaging software is set to play a pivotal role in two significant respiratory healthcare initiatives, reinforcing its growing importance in global efforts to combat complex pulmonary conditions.
In a major step forward, the Australian medtech firm has partnered with two industry players to support trials targeting chronic obstructive pulmonary disease (COPD) and other serious lung disorders. U.S.-based SMS Biotech will utilise 4DMedical’s software to assist with a human stem cell therapy trial focused on mild-to-moderate COPD. The clinical study, approved by the Australian government, will be conducted at Cabrini Health in Victoria and aims to evaluate structural and functional improvements in lung performance.
In this trial, 4DMedical’s imaging technology will assess participants’ baseline lung health and monitor the impact of therapy over time. The software’s ability to measure changes in lung airflow and structure is expected to be critical in quantifying treatment effectiveness. SMS Biotech is also pursuing early use of its therapy in the U.S. under compassionate care provisions, collaborating with leading academic medical centres.
In a separate partnership, a multinational respiratory device developer has engaged 4DMedical’s platform to enhance its clinical trial process for an innovative implantable device designed to treat complex lung diseases. The developer will use the technology to better identify suitable candidates and track their lung function throughout the trial, potentially improving both diagnostic precision and treatment evaluation.
These collaborations are part of 4DMedical’s broader commercial strategy to support pharmaceutical and medical device companies with advanced imaging tools that streamline clinical trials and optimise patient selection.
In parallel with these trials, 4DMedical has also been recognised in the U.S. healthcare space, particularly in connection with veterans’ health. Recent congressional testimony highlighted the company’s role in developing faster and less invasive diagnostic solutions for lung diseases affecting veterans exposed to harmful substances during military service. The U.S. Department of Veterans Affairs has begun integrating 4DMedical’s technology to meet increasing demands for respiratory screening.
Through a partnership with Philips (NYSE:PHG), 4DMedical is contributing to early diagnosis efforts for conditions such as interstitial lung disease, constrictive bronchiolitis and unexplained dyspnoea. Its software transforms standard CT scans into dynamic four-dimensional images, giving clinicians a clearer understanding of lung function and allowing for earlier, more accurate diagnoses.
These recent developments showcase 4DMedical’s expanding global impact and underline the value of its innovations in both clinical research and real-world healthcare applications.
